The molecular hallmark of APL is a balanced reciprocal chromosomal translocation, t(15;17), which results in a chimeric PML‐RARA fusion gene that offers a unique opportunity for measurable residual disease (MRD) monitoring via quantitative real‐time reverse‐transcription PCR (qRT‐PCR) of the PML‐RARA transcripts [4]. The gene discussed is PML; the disease is acute promyelocytic leukemia.